Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
Tardive Dystonia:Late-onset & Persistent Dystonia Caused by Antipsychotic Drugs
Neurol 32:1335-1346, Burke,R.E.,et al, 1982
Rabbit Syndrome
Neurol102:e209275, Huynh,T.U., & Beckley, E.H., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Acute Maternal Confusion and Neonatal Seizure Postpartum
BMJ 364:k5399, Jakes, A.D.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Lithium-Induced Reversible Pisa Syndrome
Neurol 88:e184, Kumar, N.,et al, 2017
A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Acute Myopia and Angle Closure Glaucoma from Topiramate in a Seven-Year-Old: A Case Report and Review of the Literature
BMC Pediatrics 14:96, Rapoport, Y.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy
NEJM 362:790-799, Glauser,T.A.,et al, 2010
High Doses of Deferiprone May Be Associated with Cerebellar Syndrome
BMJ 338:653, Beau-Salinas,F.,et al, 2009
A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008